Literature DB >> 1564966

[Type I herpes virus, HLA phenotype and Behçet disease].

J Sánchez Román1, M J Castillo Palma, R Torronteras Santiago, J M Varela Aguilar, F López Checa, F Sánchez García.   

Abstract

BACKGROUND: The pathogenic factors of Behçet's disease (BD) differentiate according to geographical zones. The aim of this study was to evaluate the possible relation between this process and infection by type I herpes simplex virus (HSV-1) in Spain.
METHODS: The prevalence of antibodies vs HSV-1 and cytomegalovirus (CMV) was studied by complement fixation in three series: A) 34 patients with BD; B) 21 with primary uveitis; C) 40 controls. HSV-1 specificity was established by ELISA. HLA typing was performed in 32 individuals from series A.
RESULTS: The frequency of anti HSV-1 in A (76%) was greater (p = 0.045) than in C (55%) and B (66%). These differences were more evident when titers equal/superior to 1/64 were considered as positive, with this being a value exceeding the 97.5% percentage of the control series (A = 21%, C = 2%, p = 0.015), specially for the ocular BD subgroup (26%, p = 0.011 with respect to C). The B series did not differ from C (p = 0.88). To the contrary no differences were observed in the distribution of titers vs CMV. Although a greater frequency of anti HSV-1 was observed in HLA-B51+ the differences were not significant (p = 0.09).
CONCLUSIONS: The frequency of evaluable titers of anti-HSV-1 is greater in patients with BD (specially with ocular involvement) than in the control series. No association was found between higher titers and HLA PB51+ phenotype.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1564966

Source DB:  PubMed          Journal:  Med Clin (Barc)        ISSN: 0025-7753            Impact factor:   1.725


  1 in total

1.  Association between HLA class I and class II alleles and the outcome of West Nile virus infection: an exploratory study.

Authors:  Marion C Lanteri; Zhanna Kaidarova; Trevor Peterson; Steven Cate; Brian Custer; Shiquan Wu; Maria Agapova; Jacqueline P Law; Thomas Bielawny; Frank Plummer; Leslie H Tobler; Mark Loeb; Michael P Busch; Jonathan Bramson; Ma Luo; Philip J Norris
Journal:  PLoS One       Date:  2011-08-01       Impact factor: 3.240

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.